Abstract 100P
Background
Rapid diagnostic services (RDS) are a two-week wait pathway for patients with non-specific symptoms (e.g., weight loss and fatigue), concerning of malignancy, that do not fulfil criteria for a site-specific cancer referral. Notoriously, patients without clear red flag symptoms have longer time to diagnosis and worse outcomes. RDS are being expanded across England to provide a new referral route for this cohort of patients to improve time to diagnosis and the patient journey. This study aimed to create a cancer risk stratification tool based on levels of standard serum biomarkers to help clinicians triage patients attending Guy’s RDC.
Methods
We analysed a panel of standard serum biomarkers assessed at referral for patients seen at Guy´s RDC between December 2016 and April 2022. Latent class analysis (LCA) was applied to investigate classes of individuals characterized based on their biomarker values (according to medical cut-offs), which were then examined as predictors of cancer using multivariate logistic regression. The abnormal biomarkers identified within LCA class with higher risk of cancer were used to create a scoring system, which was then developed into a cancer stratification tool.
Results
LCA identified four biomarker profiles: 1) normal values for all markers (51% of population); 2) abnormal values for haemoglobin, creatinine, and inflammatory markers (28%); 3) abnormal values for neutrophil to lymphocyte ratio, neutrophils, and inflammatory markers (12%); 4) abnormal values for multiple (n=10) markers (8%). Compared with class 1, class 4 had an increased risk of cancer (Odds ratio (OR) 6.33; 95% Confidence Interval (CI) 5.92-6.77). Based on the biomarkers identified in class 4 we created a score giving one point to each abnormal biomarker. A score of >=2 was associated with an increased risk of cancer (OR 3.09; 95%CI 2.91-3.27), as compared to a score of <2 (Area under the curve for test-training split: 0.68, C-index: 0.7).
Conclusions
Our innovative approach to triage patients with non-specific symptoms in the RDC for cancer diagnosis suggests that a combination of 10 standard biomarkers could be used to help facilitate a more efficient diagnosis of cancer when presenting with vague symptoms.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
83P - Evaluation of serum macrophage inhibitory cytokine 1 as a diagnostic biomarker for pancreatic cancer: A systematic review and diagnostic accuracy meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Profiling of lipid-loaded macrophages in melanoma
Presenter: Marta Pandini
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Whole-genome CRISPR screening identifies chemosensor receptors as key regulators of the cancer-macrophage crosstalk
Presenter: Giulia Marelli
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Regulation of cancer progression through the gut microbiome and immuno-nutrition
Presenter: Anikka Swaby
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Macrophage ontogeny underlies functional programs and drives brain tumor progression
Presenter: Miranda Yu
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluating the infiltration of anti-NKG2DL CAR-T cells into a 3D cell culture developed in a Vitvo cartridge bioreactor
Presenter: Aigul Valiullina
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Neutrophils as producers of endothelial growth factor in the progression of kidney cancer
Presenter: Ilseya Myagdieva
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: A systematic review
Presenter: Omar Mubarak
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Reduction in the relative lymphocyte count as a predictive biomarker for serious immune-related adverse events in patients with metastatic non-small cell lung cancer on immunotherapy: Single institution experience
Presenter: Antoan Garev
Session: Cocktail & Poster Display session
Resources:
Abstract